Sarepta Therapeutics Says FDA Accept sNDAs For AMONDYS 45 And VYONDYS 53 For Treatment Of Duchenne Muscular Dystrophy; PDUFA Target Action Data February 28, 2027

Loading news article.

Sarepta Therapeutics Says FDA Accept sNDAs For AMONDYS 45 And VYONDYS 53 For Treatment Of Duchenne Muscular Dystrophy; PDUFA Target Action Data February 28, 2027 | WAPE

Sarepta Therapeutics Says FDA Accept sNDAs For AMONDYS 45 And VYONDYS 53 For Treatment Of Duchenne Muscular Dystrophy; PDUFA Target Action Data February 28, 2027

Article summary

Related companies

Comments —